Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Li

Showing results (41-50 of 139) with videos related to

Pageof 14
Sort By:
Future Oncology (London, England)|March 31, 2025
Treatment with palbociclib and an aromatase inhibitor for people with hormone receptor-positive/ human epidermal growth factor receptor 2-negative metastatic breast cancer that has spread to the lungs or liver: a plain language summaryAdam Brufsky, Xianchen Liu, Benjamin Li, et al.
Critical Reviews in Oncology/Hematology|December 1, 2021
Willingness to pay for high-quality remote radiation oncology training in Latin AmericaBenjamin Li, Thomas Perez, Jinxuan Hao, et al.
Frontiers in Oncology|June 6, 2022
Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United StatesYousef Zakharia, Despina Thomaidou, Benjamin Li, et al.
Advances in Radiation Oncology|February 10, 2023
Targeting Education as a Barrier to Implement Hypofractionation: Results of a Country-Wide Training ProgramMaría Caicedo-Martínez, Benjamin Li, Alejandro González-Motta, et al.
Future Oncology (London, England)|March 27, 2024
Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summaryAdam Brufsky, Xianchen Liu, Benjamin Li, et al.
Frontiers in Oncology|October 16, 2023
Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or olderAdam Brufsky, Xianchen Liu, Benjamin Li, et al.
JTO Clinical and Research Reports|September 30, 2021
Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in JapanYasushi Yatabe, Yasumasa Yoshiki, Koichi Matsumura, et al.
Cancers|November 14, 2023
Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical PracticeAdam Brufsky, Xianchen Liu, Benjamin Li, et al.
The Oncologist|July 24, 2023
Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast CancerHope S Rugo, Xianchen Liu, Benjamin Li, et al.
Cardio-Oncology (London, England)|July 4, 2025
QT STAR: concomitant QTc-prolonging medication use among patients with HR+/HER2- metastatic breast cancer receiving a CDK4/6 inhibitor in first lineSusan Dent, Heather Moore, Michael Fradley, et al.
Pageof 14

Showing results (41-50 of 139) with videos related to

Sort By:
Pageof 14
Future Oncology (London, England)|March 31, 2025
Treatment with palbociclib and an aromatase inhibitor for people with hormone receptor-positive/ human epidermal growth factor receptor 2-negative metastatic breast cancer that has spread to the lungs or liver: a plain language summaryAdam Brufsky, Xianchen Liu, Benjamin Li, et al.
Critical Reviews in Oncology/Hematology|December 1, 2021
Willingness to pay for high-quality remote radiation oncology training in Latin AmericaBenjamin Li, Thomas Perez, Jinxuan Hao, et al.
Frontiers in Oncology|June 6, 2022
Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United StatesYousef Zakharia, Despina Thomaidou, Benjamin Li, et al.
Advances in Radiation Oncology|February 10, 2023
Targeting Education as a Barrier to Implement Hypofractionation: Results of a Country-Wide Training ProgramMaría Caicedo-Martínez, Benjamin Li, Alejandro González-Motta, et al.
Future Oncology (London, England)|March 27, 2024
Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summaryAdam Brufsky, Xianchen Liu, Benjamin Li, et al.
Frontiers in Oncology|October 16, 2023
Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or olderAdam Brufsky, Xianchen Liu, Benjamin Li, et al.
JTO Clinical and Research Reports|September 30, 2021
Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in JapanYasushi Yatabe, Yasumasa Yoshiki, Koichi Matsumura, et al.
Cancers|November 14, 2023
Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical PracticeAdam Brufsky, Xianchen Liu, Benjamin Li, et al.
The Oncologist|July 24, 2023
Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast CancerHope S Rugo, Xianchen Liu, Benjamin Li, et al.
Cardio-Oncology (London, England)|July 4, 2025
QT STAR: concomitant QTc-prolonging medication use among patients with HR+/HER2- metastatic breast cancer receiving a CDK4/6 inhibitor in first lineSusan Dent, Heather Moore, Michael Fradley, et al.
Pageof 14